Vivos Therapeutics, Inc. VVOS
are a revenue stage medical technology and healthcare services company that features a comprehensive suite of proprietary
oral appliances and therapeutic treatments. Our products non-surgically treat certain maxillofacial and developmental
abnormalities of the mouth and jaws that are closely associated with breathing and sleep disorders such as mild to severe
obstructive sleep apnea (known as OSA) and snoring in adults. We call the use of our appliances coupled with specific therapeutic treatment protocols The Vivos Method.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.4M | $15.0M | $13.8M | $16.0M | $16.9M | $13.1M | $11.4M | — |
| Cost of revenue | $6.9M | $6.0M | $5.5M | $200.0K | $400.0K | $100.0K | — | — |
| Gross profit | $10.5M | $9.0M | $8.3M | $10.0M | $12.6M | $10.4M | $8.7M | — |
| R&D | $100.0K | $100.0K | $100.0K | $100.0K | $200.0K | — | — | — |
| SG&A | $27.7M | $17.9M | $22.5M | $29.0M | $25.8M | $16.1M | $16.2M | — |
| Total operating expenses | $30.4M | $20.2M | $25.6M | $35.0M | $33.0M | $22.5M | $19.2M | — |
| Operating income | -$19.9M | -$11.2M | -$17.3M | -$25.0M | -$20.4M | -$12.0M | -$10.6M | — |
| Interest expense | $1.4M | — | — | — | $14.0K | $96.0K | $137.9K | — |
| Pre-tax income | -$21.2M | -$11.1M | -$13.6M | -$23.8M | -$20.3M | -$12.1M | -$10.8M | — |
| Net income | -$21.2M | -$11.1M | -$13.6M | -$23.8M | -$20.3M | -$12.1M | -$10.8M | — |
| EPS, basic | -2.07 | -2.22 | -11.14 | -25.90 | -0.96 | — | — | — |
| EPS, diluted | -2.07 | -2.22 | -11.14 | -25.90 | -0.96 | -1.40 | -0.95 | — |
| Shares, diluted (wtd. avg.) | $10.3M | $5.0M | $1.2M | $920.6K | $21.23B | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.0M | $6.3M | $1.6M | $3.5M | $24.0M | $18.2M | $469.4K | — |
| Receivables | $1.6M | $430.0K | $202.0K | $457.0K | $1.2M | $1.4M | $871.3K | — |
| Total current assets | $4.4M | $7.5M | $2.5M | $5.4M | $27.3M | $20.4M | $2.0M | — |
| Property, plant and equipment | $3.8M | $3.3M | $3.3M | $3.1M | $2.8M | $872.0K | $1.1M | — |
| Goodwill | $8.6M | $2.8M | $2.8M | $2.8M | $2.8M | $2.7M | $2.7M | — |
| Other intangibles | $4.0M | $409.0K | $420.0K | $302.0K | $341.0K | $270.0K | $689.2K | — |
| Total assets | $25.2M | $15.3M | $10.7M | $13.7M | $33.7M | $25.3M | $7.6M | — |
| Accounts payable | $1.7M | $1.1M | $2.1M | $1.4M | $920.0K | $781.0K | $1.1M | — |
| Short-term debt | $8.4M | — | — | — | $1.3M | $867.0K | $3.7M | — |
| Total current liabilities | $18.1M | $5.0M | $7.3M | $6.8M | $7.5M | $7.8M | $9.1M | — |
| Long-term debt | $469.0K | — | — | — | $1.3M | $423.0K | $3.7M | — |
| Total liabilities | $26.7M | $7.3M | $10.3M | $8.9M | $8.2M | $8.4M | $9.2M | — |
| Retained earnings | -$125.4M | -$104.2M | -$93.1M | -$79.5M | -$55.6M | -$35.3M | -$23.3M | — |
| Total equity | -$1.5M | $8.0M | $411.0K | $4.8M | $25.5M | $16.9M | -$2.9M | $4.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.3M | -$12.7M | -$11.9M | -$19.6M | -$15.7M | -$5.7M | -$5.3M | — |
| Depreciation and amortisation | $1.3M | $581.0K | $621.0K | $669.0K | $733.0K | $300.0K | $326.8K | — |
| Stock-based compensation | $661.0K | $762.0K | $1.1M | $2.4M | $2.7M | $2.2M | $2.0M | — |
| Capital expenditure | $2.3M | $568.0K | $803.0K | $924.0K | $2.4M | $120.0K | $175.6K | — |
| Investing cash flow | -$7.5M | -$568.0K | -$853.0K | -$924.0K | -$2.6M | -$120.0K | $86.2K | — |
| Financing cash flow | $18.6M | $17.9M | $10.9M | — | $24.2M | $23.5M | $4.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-016854.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |